Last reviewed 2026-04-20 · How we verify

Orally Suspension of CoV2-OGEN1

Syneos Health · Phase 1 active Small molecule Quality 0/100

Orally Suspension of CoV2-OGEN1 is a Small molecule drug developed by Syneos Health. It is currently in Phase 1 development.

At a glance

Generic name	Orally Suspension of CoV2-OGEN1
Sponsor	Syneos Health
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

First-In-Human Study Of Orally Administered CoV2-OGEN1 In Healthy Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Orally Suspension of CoV2-OGEN1 CI brief — competitive landscape report
Orally Suspension of CoV2-OGEN1 updates RSS · CI watch RSS
Syneos Health portfolio CI

Frequently asked questions about Orally Suspension of CoV2-OGEN1

What is Orally Suspension of CoV2-OGEN1?

Orally Suspension of CoV2-OGEN1 is a Small molecule drug developed by Syneos Health.

Who makes Orally Suspension of CoV2-OGEN1?

Orally Suspension of CoV2-OGEN1 is developed by Syneos Health (see full Syneos Health pipeline at /company/syneos-health).

What development phase is Orally Suspension of CoV2-OGEN1 in?

Orally Suspension of CoV2-OGEN1 is in Phase 1.

Manufacturer: Syneos Health — full pipeline
Compare: Orally Suspension of CoV2-OGEN1 vs similar drugs
Pricing: Orally Suspension of CoV2-OGEN1 cost, discount & access